• Je něco špatně v tomto záznamu ?

Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients

K. Cerna, D. Duricova, M. Hindos, J. Hindos Hrebackova, M. Lukas, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, K. Kastylova, V. Teplan, M. Lukas

. 2022 ; 16 (9) : 1347-1353. [pub] 2022Sep08

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024450

Grantová podpora
IBD-COMFORT Foundation

BACKGROUND AND AIMS: Knowledge on the immunogenicity of anti-SARS-CoV-2 vaccines in inflammatory bowel disease [IBD] patients is limited. Therefore, SARS-CoV-2-specific T-cell responses and antibodies were analysed in 60 IBD vaccine recipients and 30 controls. METHODS: SARS-CoV-2 IgG antibodies against the viral spike protein were measured at baseline and at 8 and 26 weeks after the second vaccine dose. SARS-CoV-2 IgG antibodies against the nucleocapsid antigens were measured at week 26. A SARS-CoV-2 interferon-gamma released assay [IGRA] was performed in all vaccinees at week 26. RESULTS: At weeks 0 and 8, no differences were found in anti-spike antibodies between cohorts. At week 26, the decrease in antibody levels was more significant in the IBD cohort compared to the healthy cohort, and anti-nucleocapsid antibodies were not detected in either group. At week 26, 16 of 90 [18%] vaccinated individuals had a negative IGRA test result, seven of 90 [8%] were borderline and 67 [74%] had a positive IGRA result; 22 of the 23 individuals with negative or borderline IGRA results belonged to the IBD cohort. However, the overall functional ability of T-lymphocytes to produce interferon-gamma after the unspecific mitogen stimulation was lower in IBD patients. In vaccinated individuals with low or borderline IGRA, treatment with tumour necrosis factor-alpha inhibitors was the most frequent. In individuals with a significant drop in anti-spike antibody levels, plasmatic interferon-gamma concentrations after the specific SARS-CoV-2 stimulation were also insufficient. CONCLUSIONS: Simple humoral and cellular post-vaccination monitoring is advisable in IBD patients so that repeated vaccine doses may be scheduled.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024450
003      
CZ-PrNML
005      
20221031100310.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjac048 $2 doi
035    __
$a (PubMed)35358307
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Cerna, Karin $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u GENNET Prague, Czech Republic $1 https://orcid.org/0000000315935899
245    10
$a Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients / $c K. Cerna, D. Duricova, M. Hindos, J. Hindos Hrebackova, M. Lukas, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, K. Kastylova, V. Teplan, M. Lukas
520    9_
$a BACKGROUND AND AIMS: Knowledge on the immunogenicity of anti-SARS-CoV-2 vaccines in inflammatory bowel disease [IBD] patients is limited. Therefore, SARS-CoV-2-specific T-cell responses and antibodies were analysed in 60 IBD vaccine recipients and 30 controls. METHODS: SARS-CoV-2 IgG antibodies against the viral spike protein were measured at baseline and at 8 and 26 weeks after the second vaccine dose. SARS-CoV-2 IgG antibodies against the nucleocapsid antigens were measured at week 26. A SARS-CoV-2 interferon-gamma released assay [IGRA] was performed in all vaccinees at week 26. RESULTS: At weeks 0 and 8, no differences were found in anti-spike antibodies between cohorts. At week 26, the decrease in antibody levels was more significant in the IBD cohort compared to the healthy cohort, and anti-nucleocapsid antibodies were not detected in either group. At week 26, 16 of 90 [18%] vaccinated individuals had a negative IGRA test result, seven of 90 [8%] were borderline and 67 [74%] had a positive IGRA result; 22 of the 23 individuals with negative or borderline IGRA results belonged to the IBD cohort. However, the overall functional ability of T-lymphocytes to produce interferon-gamma after the unspecific mitogen stimulation was lower in IBD patients. In vaccinated individuals with low or borderline IGRA, treatment with tumour necrosis factor-alpha inhibitors was the most frequent. In individuals with a significant drop in anti-spike antibody levels, plasmatic interferon-gamma concentrations after the specific SARS-CoV-2 stimulation were also insufficient. CONCLUSIONS: Simple humoral and cellular post-vaccination monitoring is advisable in IBD patients so that repeated vaccine doses may be scheduled.
650    _2
$a protilátky virové $7 D000914
650    12
$a COVID-19 $x prevence a kontrola $7 D000086382
650    _2
$a vakcíny proti COVID-19 $7 D000086663
650    _2
$a lidé $7 D006801
650    _2
$a humorální imunita $7 D056724
650    _2
$a imunoglobulin G $7 D007074
650    12
$a idiopatické střevní záněty $x farmakoterapie $7 D015212
650    _2
$a interferon gama $7 D007371
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a vakcinace $7 D014611
650    12
$a virové vakcíny $7 D014765
655    _2
$a časopisecké články $7 D016428
700    1_
$a Duricova, Dana $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hindos, Miroslav $u AGILAB Group s.r.o., Prague, Czech Republic
700    1_
$a Hindos Hrebackova, Jana $u AGILAB Group s.r.o., Prague, Czech Republic
700    1_
$a Lukas, Martin $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic
700    1_
$a Machkova, Nadezda $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hruba, Veronika $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mitrova, Katarina $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kubickova, Kristyna $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kastylova, Kristyna $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Teplan, Vladimir $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Postgradual Medical Education, PragueCzech Republic $u Department of Internal Medicine, University Hospital and Medical Faculty, Ostrava, Czech Republic
700    1_
$a Lukas, Milan $u Clinical and Research Centre for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00166945 $t Journal of Crohn's and colitis $x 1876-4479 $g Roč. 16, č. 9 (2022), s. 1347-1353
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35358307 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100307 $b ABA008
999    __
$a ok $b bmc $g 1854264 $s 1175740
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 16 $c 9 $d 1347-1353 $e 2022Sep08 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
GRA    __
$p IBD-COMFORT Foundation
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace